Back to search
FDAFDA · Food and drugs·Recall number D-1294-2022

Irbesartan Tablets, USP, 75 mg, 90- count bottle, Rx only, Manufactured by: Jubilant Generics Ltd. Roorkee- 247661, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA, NDC 59746-447-90

Published August 3, 2022 · Recall initiated: July 18, 2022

Summary

FDA records drug Class II recall D-1294-2022, published August 3, 2022 and initiated July 18, 2022. Recalling firm: Jubilant Cadista Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 28,560 bottles; Lot: Lot #: IB120012A, IB120013A, IB120014A Exp. date 08/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if IRBESARTAN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
IRBESARTAN
Manufacturer
Jubilant Cadista Pharmaceuticals, Inc.
Distributor
Nationwide within the United States
UPC
0359746447304
Lot
Lot #: IB120012A, IB120013A, IB120014A Exp. date 08/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Irbesartan Tablets, USP, 75 mg, 90- count bottle, Rx only, Manufactured by: Jubilant Generics Ltd. Roorkee- 247661, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA, NDC 59746-447-90 recalled?

Yes. FDA published recall D-1294-2022 on August 3, 2022. Reported hazard: Failed Dissolution Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: IRBESARTAN. UPC: 0359746447304.